Sanofi’s Sarclisa gains new US multiple myeloma indicationThe FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, Share XSanofi’s Sarclisa gains new US multiple myeloma indicationhttps://pharmaphorum.com/news/sanofis-sarclisa-gains-new-us-multiple-myeloma-indication/
Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myelomaSanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells Share XKiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myelomahttps://pharmaphorum.com/news/sanofi-to-develop/
Sanofi builds case for Sarclisa, challenging J&J’s DarzalexSanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Share XSanofi builds case for Sarclisa, challenging J&J’s Darzalexhttps://pharmaphorum.com/news/sanofi-builds-case-for-sarclisa-challenging-jjs-darzalex/
Sanofi gets first OK for isatuximab for myeloma, challenging J&J’s DarzalexSanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming Share XSanofi gets first OK for isatuximab for myeloma, challenging J&J’s Darzalexhttps://pharmaphorum.com/news/sanofi-gets-first-ok-for-isatuximab-for-myeloma-challenging-jjs-darzalex/
